Next-generation pharmacogenomics: systematic integration of genetics, physiology, and drug-drug interactions (PGxOMICS)

Research on the factors influencing drug efficacy and adverse drug reactions has been fragmented and primarily limited to small clinical studies. To move beyond current limitations, this proposal aims to develop a broad and systematic approach towards pharmacogenomics. We plan to integrate data on systematically assessed genetic variation, physiology, co-medications, age, and sex to explore their interactions and impact on treatment outcomes using real-world data of large-scale biobanks coupled with comprehensively annotated genomic information. Leveraging extensive phenotype data mined from electronic health records using large language models, alongside the discovery, validation and improved imputation of novel and known genetic variants will allow systematic modelling across genetic and physiological domains. This approach lays the groundwork for developing advanced risk prediction models for pharmacogenomics, ultimately leading to improved personalized treatment for individuals.